Ilika ships first Stereax M300 prototypes

Ilika

Ilika plc (LON:IKA), the UK pioneer in solid state battery technology, has announced it has commenced shipping prototype Stereax M300s to customers, meeting an important commercial milestone.

These initial deliveries will be allocated to the 21 customers which form Ilika’s existing order book, many of whom have previously received Stereax batteries for evaluation from the Company’s UK pilot line. A number of batteries from the initial batches will be allocated to the extensive M300 testing programme, which is designed to generate a larger body of test data relevant to exciting applications in active implantable medical devices (AIMDs). Applications include powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices. With its small footprint and enhanced charging capabilities, Stereax is ideally suited to meet the needs of AIMDs, offering benefits that include: reduced surgery time, the ability to place the implant closer to the point of therapy, long-lasting performance, user recharging at home and the ability to power Bluetooth radio. Ilika and its strategic partner, Cirtec Medical Corp, will solicit feedback from this core customer group to verify customer experience before ramping production.

This milestone progresses the 10-year manufacturing agreement signed in August 2023, in which Cirtec Medical, a leading US medical device manufacturer, will produce Ilika’s Stereax battery portfolio.

Daniel Weinstein, Co-Founder and Chief Executive Officer at Lura Health, a provider of non-invasive health management solutions using continuous salivary monitoring, said: “As one of the first customers to receive M300 prototypes, we are excited to be working with Ilika and Cirtec Medical to demonstrate the deployment of Stereax miniature batteries in our range of non-invasive microsensors for salivary health markers.”

Shawn Martin, Vice President at Cirtec Medical, said: “The Stereax product is an excellent addition to our world-leading capabilities in advanced miniaturised electronics designed for life-changing medical devices.”

Graeme Purdy, CEO of Ilika, said: “After successfully transferring Stereax technology to Cirtec Medical’s world-class manufacturing facility in Lowell, Massachusetts, we are looking forward to intensifying our customer engagement and servicing their needs for implantable power management devices. The applications form a market of over $40bn with high single digit CAGR, with the miniature battery component alone worth over $250m.”

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Ilika reports first Stereax revenues and Goliath progress

Ilika expects FY26 revenue of approximately £1.1m, including first commercial Stereax electrode sales, with Goliath evaluation activity expanding across automotive, defence and e-bike applications.

Defence battery demand highlights strategic opening for Ilika

Ilika highlights how rising defence and energy security demands are expanding the commercial opportunity for advanced battery technologies across military and infrastructure markets.

Ilika to showcase Stereax batteries to medical device manufacturers

Ilika’s Stereax batteries will be represented at Medical Technology Ireland 2026, giving the company direct exposure to medical device manufacturers and suppliers.

Ilika puts Stereax in front of medical device buyers

Ilika’s Stereax batteries will be represented at MEDevice Silicon Valley, putting the technology in front of medical device buyers and engineers.

Ilika to present solid-state battery progress at major UK energy storage conference

Ilika will present its Goliath quasi-solid-state cell technology at the Faraday Institution Conference 2026, giving investors a clear positioning update.

Search